Published in Invest Ophthalmol Vis Sci on June 23, 2010
Consequences of oxidative stress in age-related macular degeneration. Mol Aspects Med (2012) 1.59
Changes in retinal sensitivity in geographic atrophy progression as measured by microperimetry. Invest Ophthalmol Vis Sci (2011) 0.94
Geographic atrophy in patients with advanced dry age-related macular degeneration: current challenges and future prospects. Clin Ophthalmol (2015) 0.91
670-nm light treatment reduces complement propagation following retinal degeneration. J Neuroinflammation (2012) 0.90
Clinical characteristics and current treatment of age-related macular degeneration. Cold Spring Harb Perspect Med (2014) 0.87
Age-Related Macular Degeneration: Advances in Management and Diagnosis. J Clin Med (2015) 0.87
A longitudinal follow-up study of saffron supplementation in early age-related macular degeneration: sustained benefits to central retinal function. Evid Based Complement Alternat Med (2012) 0.86
Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial. Invest Ophthalmol Vis Sci (2013) 0.85
Antioxidant drug therapy approaches for neuroprotection in chronic diseases of the retina. Int J Mol Sci (2014) 0.85
Bowman lecture on the role of inflammation in degenerative disease of the eye. Eye (Lond) (2013) 0.84
[Therapy approaches for geographic atrophy]. Ophthalmologe (2010) 0.83
Current therapeutic developments in atrophic age-related macular degeneration. Br J Ophthalmol (2015) 0.83
Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis. Recent Pat Biomed Eng (2012) 0.82
Apigenin Attenuates Oxidative Injury in ARPE-19 Cells thorough Activation of Nrf2 Pathway. Oxid Med Cell Longev (2016) 0.79
Dry age-related macular degeneration: A currently unmet clinical need. Intractable Rare Dis Res (2012) 0.78
Age-related macular degeneration. Clin Ophthalmol (2011) 0.78
Nano chitosan peptide as a potential therapeutic carrier for retinal delivery to treat age-related macular degeneration. Mol Vis (2012) 0.77
CLINICAL ENDPOINTS FOR THE STUDY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Retina (2016) 0.75
Nrf2 Is an Attractive Therapeutic Target for Retinal Diseases. Oxid Med Cell Longev (2016) 0.75
Nitroxide pharmaceutical development for age-related degeneration and disease. Front Genet (2015) 0.75
Integrated Approaches to Drug Discovery for Oxidative Stress-Related Retinal Diseases. Oxid Med Cell Longev (2016) 0.75
Aging: a theory based on free radical and radiation chemistry. J Gerontol (1956) 20.39
The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol (2000) 8.10
Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci U S A (2002) 6.47
Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol (2004) 5.14
Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology (2001) 5.06
Evolution of geographic atrophy of the retinal pigment epithelium. Eye (Lond) (1988) 4.47
Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology (2007) 3.96
Oxidative damage-induced inflammation initiates age-related macular degeneration. Nat Med (2008) 3.92
A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9. Arch Ophthalmol (2001) 3.49
Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration. Ophthalmology (1999) 2.26
High-resolution spectral domain-OCT imaging in geographic atrophy associated with age-related macular degeneration. Invest Ophthalmol Vis Sci (2008) 2.03
Fixation patterns and reading rates in eyes with central scotomas from advanced atrophic age-related macular degeneration and Stargardt disease. Ophthalmology (1996) 1.93
A2E-epoxides damage DNA in retinal pigment epithelial cells. Vitamin E and other antioxidants inhibit A2E-epoxide formation. J Biol Chem (2003) 1.83
The long-term natural history of geographic atrophy from age-related macular degeneration: enlargement of atrophy and implications for interventional clinical trials. Ophthalmology (2007) 1.63
Risk factors of age-related maculopathy in a population 70 years of age or older. Ophthalmology (1996) 1.61
Retinal precursors and the development of geographic atrophy in age-related macular degeneration. Ophthalmology (2007) 1.59
Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26. Arch Ophthalmol (2009) 1.53
Chronic cigarette smoke causes oxidative damage and apoptosis to retinal pigmented epithelial cells in mice. PLoS One (2008) 1.40
Scanning laser ophthalmoscopic analysis of the pattern of visual loss in age-related geographic atrophy of the macula. Am J Ophthalmol (1995) 1.39
Natural history of drusenoid pigment epithelial detachment in age-related macular degeneration: Age-Related Eye Disease Study Report No. 28. Ophthalmology (2010) 1.32
Issues in quantifying atrophic macular disease using retinal autofluorescence. Retina (2006) 1.26
The epidemiology of progression of pure geographic atrophy: the Beaver Dam Eye Study. Am J Ophthalmol (2008) 1.17
N(epsilon)(carboxymethyl)lysin and the AGE receptor RAGE colocalize in age-related macular degeneration. Invest Ophthalmol Vis Sci (1999) 1.16
New therapeutic targets in atrophic age-related macular degeneration. Expert Opin Ther Targets (2007) 1.16
Modelling the natural history of geographic atrophy in patients with age-related macular degeneration. Ophthalmic Epidemiol (2005) 1.11
Analysis of digital scanning laser ophthalmoscopy fundus autofluorescence images of geographic atrophy in advanced age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2002) 1.09
Low luminance visual dysfunction as a predictor of subsequent visual acuity loss from geographic atrophy in age-related macular degeneration. Ophthalmology (2008) 1.06
Protective effect of TEMPOL derivatives against light-induced retinal damage in rats. Invest Ophthalmol Vis Sci (2007) 1.03
Cellular sites of H2O2-induced damage and their protection by nitroxides. Biochim Biophys Acta (2001) 0.95
Neuroprotective effects of TEMPOL in central and peripheral nervous system models of Parkinson's disease. Biochem Pharmacol (2005) 0.94
Designing clinical trials for age-related geographic atrophy of the macula: enrollment data from the geographic atrophy natural history study. Retina (2007) 0.93
Improvement of visual acuity over time in patients with bilateral geographic atrophy from age-related macular degeneration. Retina (2000) 0.91
Asymptomatic peripapillary subretinal hemorrhage: a study of 10 cases. J Neuroophthalmol (2008) 0.90
Selective retina therapy (SRT) in patients with geographic atrophy due to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2009) 0.88
Nitroxides block DNA scission and protect cells from oxidative damage. Biochemistry (1991) 0.87
OT-674 suppresses photooxidative processes initiated by an RPE lipofuscin fluorophore. Photochem Photobiol (2008) 0.85
Comparison of fundus autofluorescence of age-related macular degeneration between a fundus camera and a confocal scanning laser ophthalmoscope. Osaka City Med J (2009) 0.83
Complement factor H polymorphism in age-related macular degeneration. Science (2005) 31.10
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology (2012) 11.91
Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med (2010) 10.75
Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology (2010) 10.28
A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J Ophthalmol (2003) 9.99
Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology (2003) 8.98
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med (2015) 7.08
von Hippel-Lindau disease. Lancet (2003) 6.20
The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol (2005) 4.46
Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. Proc Natl Acad Sci U S A (2010) 4.30
Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology (2011) 4.15
Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina (2006) 3.98
Seven new loci associated with age-related macular degeneration. Nat Genet (2013) 3.81
A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol (2005) 3.74
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation (2008) 3.63
Age-related macular degeneration. Lancet (2008) 3.34
Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina (2006) 3.29
Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology (2005) 3.28
Increased prevalence of myopia in the United States between 1971-1972 and 1999-2004. Arch Ophthalmol (2009) 3.21
Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol (2003) 3.17
Prevalence of refractive error in the United States, 1999-2004. Arch Ophthalmol (2008) 3.06
The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog Retin Eye Res (2005) 3.03
The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22. Arch Ophthalmol (2007) 3.02
Panretinal photocoagulation for proliferative diabetic retinopathy. N Engl J Med (2011) 2.98
Diabetic retinopathy. Diabetes Care (2004) 2.97
Visual acuity as an outcome measure in clinical trials of retinal diseases. Ophthalmology (2007) 2.69
Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology (2012) 2.68
Unraveling a multifactorial late-onset disease: from genetic susceptibility to disease mechanisms for age-related macular degeneration. Annu Rev Genomics Hum Genet (2009) 2.40
Characterization of birdshot chorioretinopathy using extramacular enhanced depth optical coherence tomography. JAMA Ophthalmol (2013) 2.36
The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology (2013) 2.35
Fundus autofluorescence imaging of the white dot syndromes. Arch Ophthalmol (2010) 2.26
Signal strength is an important determinant of accuracy of nerve fiber layer thickness measurement by optical coherence tomography. J Glaucoma (2009) 2.19
The relationship of dietary lipid intake and age-related macular degeneration in a case-control study: AREDS Report No. 20. Arch Ophthalmol (2007) 2.12
The involvement of sequence variation and expression of CX3CR1 in the pathogenesis of age-related macular degeneration. FASEB J (2004) 2.04
The relationship of dietary omega-3 long-chain polyunsaturated fatty acid intake with incident age-related macular degeneration: AREDS report no. 23. Arch Ophthalmol (2008) 1.93
Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci (2005) 1.92
Factors associated with variability in retinal nerve fiber layer thickness measurements obtained by optical coherence tomography. Ophthalmology (2007) 1.91
Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women: the Women's Antioxidant and Folic Acid Cardiovascular Study. Arch Intern Med (2009) 1.83
Evaluation of time domain and spectral domain optical coherence tomography in the measurement of diabetic macular edema. Invest Ophthalmol Vis Sci (2008) 1.83
Risk assessment model for development of advanced age-related macular degeneration. Arch Ophthalmol (2011) 1.75
Area of peripheral retinal nonperfusion and treatment response in branch and central retinal vein occlusion. Retina (2014) 1.70
Risk of advanced age-related macular degeneration after cataract surgery in the Age-Related Eye Disease Study: AREDS report 25. Ophthalmology (2008) 1.69
Acute macular neuroretinopathy: long-term insights revealed by multimodal imaging. Retina (2012) 1.68
Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. Arch Ophthalmol (2010) 1.68
Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina (2009) 1.67
The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology (2012) 1.66
Blindness and visual impairment: a public health issue for the future as well as today. Arch Ophthalmol (2004) 1.63
Low-dose aspirin and medical record-confirmed age-related macular degeneration in a randomized trial of women. Ophthalmology (2009) 1.62
National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS Report No. 10. Arch Ophthalmol (2003) 1.61
Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology (2008) 1.60
Retinal precursors and the development of geographic atrophy in age-related macular degeneration. Ophthalmology (2007) 1.59
Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci (2008) 1.58
Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26. Arch Ophthalmol (2009) 1.53
Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology (2011) 1.52
Synergic effect of polymorphisms in ERCC6 5' flanking region and complement factor H on age-related macular degeneration predisposition. Proc Natl Acad Sci U S A (2006) 1.52
Prevalence of posterior subcapsular cataracts in volunteer cytapheresis donors. Transfusion (2010) 1.51
An electronic medical records system for clinical research and the EMR EDC interface. Invest Ophthalmol Vis Sci (2007) 1.48
Evaluation of age-related macular degeneration with optical coherence tomography. Surv Ophthalmol (2012) 1.47
Intravitreal anti-vascular endothelial growth factor therapy with pegaptanib for advanced von Hippel-Lindau disease of the retina. Retina (2007) 1.46
{omega}-3 Long-chain polyunsaturated fatty acid intake and 12-y incidence of neovascular age-related macular degeneration and central geographic atrophy: AREDS report 30, a prospective cohort study from the Age-Related Eye Disease Study. Am J Clin Nutr (2009) 1.44
Macular telangiectasia type 2. Prog Retin Eye Res (2012) 1.44
Does long-term aspirin use increase the risk of neovascular age-related macular degeneration? Expert Opin Drug Saf (2014) 1.41
Vitamin E and the age-related eye disease study supplementation for age-related macular degeneration. Arch Ophthalmol (2005) 1.40
Identification of a rare coding variant in complement 3 associated with age-related macular degeneration. Nat Genet (2013) 1.39
SD OCT features of dry arcuate longstanding retinal folds. Eur J Ophthalmol (2011) 1.38
Relationship between optical coherence tomography retinal parameters and visual acuity in diabetic macular edema. Ophthalmology (2010) 1.38
Evaluation of optical coherence tomography retinal thickness parameters for use in clinical trials for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci (2009) 1.36
Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes: early treatment diabetic retinopathy study report no. 27. Diabetes Care (2005) 1.34
Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci (2008) 1.33
Natural history of drusenoid pigment epithelial detachment in age-related macular degeneration: Age-Related Eye Disease Study Report No. 28. Ophthalmology (2010) 1.32
Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4. JAMA Ophthalmol (2013) 1.31
Relationship between photoreceptor outer segment length and visual acuity in diabetic macular edema. Retina (2010) 1.30
The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study. Ophthalmology (2003) 1.30
The prevalence of macular telangiectasia type 2 in the Beaver Dam eye study. Am J Ophthalmol (2010) 1.29
Heritability of the severity of diabetic retinopathy: the FIND-Eye study. Invest Ophthalmol Vis Sci (2008) 1.29
Hypomethylation of the IL17RC promoter associates with age-related macular degeneration. Cell Rep (2012) 1.28
Spatial distribution of posterior pole choroidal thickness by spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci (2011) 1.28